https://www.yiliao.com/index.php?action=history&feed=atom&title=ASP3082
ASP3082 - 版本历史
2026-04-18T03:48:38Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=ASP3082&diff=313623&oldid=prev
2026年1月7日 (三) 09:19 77921020
2026-01-07T09:19:18Z
<p></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="zh-Hans-CN">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">←上一版本</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">2026年1月7日 (三) 09:19的版本</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l84" >第84行：</td>
<td colspan="2" class="diff-lineno">第84行：</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <p style="margin: 0; color: #334155; line-height: 2;"></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <p style="margin: 0; color: #334155; line-height: 2;"></div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div> [[PROTAC]] • [[靶向蛋白降解 (TPD)]] • [[KRAS G12D]] • [[E3 泛素连接酶]] • [[RMC-6236]] • [[<del class="diffchange diffchange-inline">胰腺癌</del>]]</div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> [[PROTAC]] • [[靶向蛋白降解 (TPD)]] • [[KRAS G12D]] • [[E3 泛素连接酶]] • [[RMC-6236]] • [[<ins class="diffchange diffchange-inline">HRS-4642</ins>]]</div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </p></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </p></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </div></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </div></div></td></tr>
<tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l116" >第116行：</td>
<td colspan="2" class="diff-lineno">第116行：</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <tr style="border-bottom: 1px solid #f1f5f9;"></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <tr style="border-bottom: 1px solid #f1f5f9;"></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <td style="width: 95px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right;">直接竞品</td></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <td style="width: 95px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right;">直接竞品</td></div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div> <td style="padding: 10px 15px; color: #334155;">[[RMC-6236]] (分子胶) • [[MRTX1133]] <del class="diffchange diffchange-inline">(非共价抑制剂)</del></td></div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> <td style="padding: 10px 15px; color: #334155;">[[RMC-6236]] (分子胶) • [[MRTX1133]] <ins class="diffchange diffchange-inline">• [[HRS-4642]]</ins></td></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </tr></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </tr></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <tr></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <tr></div></td></tr>
</table>
77921020
https://www.yiliao.com/index.php?title=ASP3082&diff=313622&oldid=prev
77921020：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-07T09:16:25Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 2.2px solid #0f172a; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[ASP3082]]</strong> 是由 <strong>[[Astellas Pharma]]</strong>（安斯泰来）研发的一种首创性（First-in-Class）、高选择性的 <strong>[[KRAS G12D]]</strong> 靶向蛋白降解剂（<strong>[[PROTAC]]</strong>）。与传统的激酶抑制剂不同，ASP3082 利用细胞自身的 <strong>[[泛素-蛋白酶体系统]] (UPS)</strong>，通过同时结合 KRAS G12D 突变体和 <strong>[[E3 泛素连接酶]]</strong>，诱导致癌蛋白的泛素化并彻底降解。2026 年临床数据显示，该药物在 KRAS G12D 突变的 <strong>[[胰腺癌]]</strong>、<strong>[[结直肠癌]]</strong> 和 <strong>[[非小细胞肺癌]]</strong> 中显示出显著的剂量依赖性抗肿瘤活性，是“事件驱动型”药理学的代表作。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 320px; float: right; margin: 0 0 25px 25px; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">ASP3082</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">KRAS G12D Degrader (PROTAC) · 点击展开</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
<br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">机制：靶向蛋白降解 (TPD)</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.82em;"><br />
<tr style="background-color: #f8fafc;"><th colspan="2" style="padding: 5px; color: #1e40af; border-bottom: 1px solid #e2e8f0;">药物概览 (2026)</th></tr><br />
<tr><th style="text-align: left; padding: 6px 10px; border-bottom: 1px dotted #e2e8f0; color: #475569;">研发代码</th><td style="padding: 6px 10px; border-bottom: 1px dotted #e2e8f0;">ASP3082</td></tr><br />
<tr><th style="text-align: left; padding: 6px 10px; border-bottom: 1px dotted #e2e8f0; color: #475569;">药物类型</th><td style="padding: 6px 10px; border-bottom: 1px dotted #e2e8f0;">[[PROTAC]] / 降解剂</td></tr><br />
<tr><th style="text-align: left; padding: 6px 10px; border-bottom: 1px dotted #e2e8f0; color: #475569;">核心靶点</th><td style="padding: 6px 10px; border-bottom: 1px dotted #e2e8f0;">[[KRAS G12D]] (高选择性)</td></tr><br />
<tr><th style="text-align: left; padding: 6px 10px; border-bottom: 1px dotted #e2e8f0; color: #475569;">给药途径</th><td style="padding: 6px 10px; border-bottom: 1px dotted #e2e8f0;">静脉注射 (IV)</td></tr><br />
<br />
<tr style="background-color: #f8fafc;"><th colspan="2" style="padding: 5px; color: #1e40af; border-bottom: 1px solid #e2e8f0; border-top: 1px solid #e2e8f0;">临床与研发</th></tr><br />
<tr><th style="text-align: left; padding: 6px 10px; border-bottom: 1px dotted #e2e8f0; color: #475569;">研发公司</th><td style="padding: 6px 10px; border-bottom: 1px dotted #e2e8f0;">[[Astellas Pharma]]</td></tr><br />
<tr><th style="text-align: left; padding: 6px 10px; border-bottom: 1px dotted #e2e8f0; color: #475569;">核心适应症</th><td style="padding: 6px 10px; border-bottom: 1px dotted #e2e8f0;">[[胰腺癌]], [[结直肠癌]]</td></tr><br />
<tr><th style="text-align: left; padding: 6px 10px; color: #475569;">临床阶段</th><td style="padding: 6px 10px; font-weight: bold; color: #059669;">Phase I/II (扩展队列)</td></tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子药理：从“占位”到“摧毁”</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
ASP3082 采用了独特的异双功能分子设计（Heterobifunctional Molecule），其作用机制具有催化循环特性：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>双头抓取：</strong> 药物的一端特异性结合 <strong>[[KRAS G12D]]</strong> 突变蛋白，另一端招募 <strong>[[E3 泛素连接酶]]</strong>（通常利用 VHL 或 CRBN 系统）。</li><br />
<li style="margin-bottom: 12px;"><strong>三元复合物形成：</strong> 药物通过 Linker 拉近靶蛋白与连接酶的距离，形成稳定的[[三元复合物]]。这使得 E3 连接酶能够将[[泛素]]链转移至 KRAS 蛋白表面。</li><br />
<li style="margin-bottom: 12px;"><strong>催化降解：</strong> 被泛素标记的 KRAS G12D 随后被细胞内的 <strong>[[26S 蛋白酶体]]</strong> 识别并降解。释放出来的 ASP3082 分子可再次参与下一轮循环。这种<strong>[[事件驱动 (Event-driven)]]</strong> 模式使其能以较低浓度清除高丰度的致癌蛋白。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026 临床数据矩阵 (NCT05382559)</h2><br />
<div style="overflow-x: auto; margin: 30px auto;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.95em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a;">癌种分类</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">G12D 突变频率</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">ASP3082 临床表现 (2026)</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[胰腺导管腺癌]] (PDAC)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">约 40% - 50%</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>核心突破区：</strong> 对标准化疗耐药的患者，ORR 达到 25-30%，且深度降解与肿瘤缩小高度相关。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[结直肠癌]] (CRC)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">约 12% - 15%</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">单药有效，但常受 [[EGFR 反馈]] 限制。2026 趋势为联合 [[西妥昔单抗]]。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[非小细胞肺癌]] (NSCLC)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">约 4% - 5%</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">显示出持久的疾病控制，特别是对于吸烟相关肺癌患者。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">治疗策略与竞争格局</h2><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>给药方式的考量：</strong> ASP3082 目前为 <strong>[[静脉注射 (IV)]]</strong> 给药。相比于口服的 Pan-KRAS 抑制剂（如 [[RMC-6236]]），其给药便利性稍逊，但能够通过精准入血维持有效的血药浓度，适合依从性差或胃肠吸收障碍的重症患者。</li><br />
<li style="margin-bottom: 12px;"><strong>“降解”与“抑制”之争：</strong> 与非共价抑制剂（抑制活性）相比，降解剂（清除蛋白）理论上能更彻底地阻断信号，消除支架蛋白功能 (Scaffolding function)，从而克服部分适应性耐药。</li><br />
<li style="margin-bottom: 12px;"><strong>安全性特征：</strong> 2026 年安全性汇总显示，ASP3082 未出现显著的脱靶毒性，主要不良反应为输注相关反应及轻度疲劳，这得益于其对 G12D 突变体极高的选择性。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<p style="margin: 0; color: #334155; line-height: 2;"><br />
[[PROTAC]] • [[靶向蛋白降解 (TPD)]] • [[KRAS G12D]] • [[E3 泛素连接酶]] • [[RMC-6236]] • [[胰腺癌]]<br />
</p><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.5px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献 [Academic Review & Verified]</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Nagashima T, et al. (2022/2023).</strong> <em>Discovery of ASP3082, a Novel, Highly Selective, and Potent KRAS G12D Degrader.</em> <strong>[[Cancer Research]] (AACR Annual Meeting Abstract)</strong>.<br><br />
<span style="color: #475569;">[原研披露]：Astellas 团队首次公开 ASP3082 的化学结构与临床前数据，证明了其在体内外模型中对 G12D 的深度降解能力。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Bekaii-Saab TS, et al. (2023/2024).</strong> <em>A Phase 1 Study of ASP3082, a KRAS G12D Degrader, in Patients with Advanced Solid Tumors.</em> <strong>[[ESMO Congress]]</strong>.<br><br />
<span style="color: #475569;">[临床首发]：报道了 ASP3082 在人体试验中的初步安全性与药代动力学数据，确立了其作为首个临床阶段 KRAS G12D PROTAC 的地位。</span><br />
</p><br />
<br />
<p style="margin: 12px 0;"><br />
[3] <strong>Békés M, Langley DR, Crews CM. (2022).</strong> <em>PROTAC targeted protein degraders: the past is prologue.</em> <strong>[[Nature Reviews Drug Discovery]]</strong>. 21:181–200.<br><br />
<span style="color: #475569;">[领域综述]：虽然不专述 ASP3082，但作为该领域的权威综述，详细阐释了 PROTAC 克服“不可成药”靶点（如 KRAS）的理论基础。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1.5px solid #0f172a; border-radius: 8px; overflow: hidden; font-size: 0.9em;"><br />
<div style="background-color: #0f172a; color: #ffffff; text-align: center; font-weight: bold; padding: 10px; letter-spacing: 1px;">ASP3082 · 知识图谱导航</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 95px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right;">核心技术</td><br />
<td style="padding: 10px 15px; color: #334155;">[[PROTAC]] • [[E3 连接酶]] • [[泛素化]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 95px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right;">直接竞品</td><br />
<td style="padding: 10px 15px; color: #334155;">[[RMC-6236]] (分子胶) • [[MRTX1133]] (非共价抑制剂)</td><br />
</tr><br />
<tr><br />
<td style="width: 95px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right;">适应症</td><br />
<td style="padding: 10px 15px; color: #334155;">[[胰腺导管腺癌]] • [[结直肠癌]] • [[非小细胞肺癌]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
77921020